Werewolf Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Werewolf Therapeutics, Inc. filed a Form 8-K reporting the results of its annual meeting of stockholders held on June 1, 2022. The company is a Delaware corporation whose common stock trades on the Nasdaq Global Select Market under the symbol HOWL.
Meeting results and key corporate actions
- Director elections: Stockholders elected Briggs Morrison, M.D., and Michael Sherman, M.B.A., as Class I directors, each for a three-year term ending at the 2025 annual meeting.
- Briggs Morrison, M.D.: 17,938,193 votes for, 2,381,728 votes withheld, and 3,626,970 broker non-votes.
- Michael Sherman, M.B.A.: 18,192,779 votes for, 2,127,142 votes withheld, and 3,626,970 broker non-votes.
- Auditor ratification: Stockholders ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Auditor vote: 23,945,185 votes for, 1,694 votes against, and 12 abstentions.
Financial metrics and material changes
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics. It does not report a material change in financial condition versus a prior comparable period.
Guidance, outlook, risks, and unusual items
The filing contains no management guidance, business outlook, risk update, contingency, or unusual financial item. The primary disclosed matters are the director elections and auditor ratification.
Important facts for investors to verify
- Confirm the elected directors’ continued service and the composition of the board following the 2022 annual meeting.
- Review subsequent filings for any developments involving Deloitte & Touche LLP or changes in the company’s independent auditor.
- Consult the company’s periodic reports for financial performance, cash runway, financing needs, clinical-program updates, and related risks, none of which are addressed in this Form 8-K.